LoginRegister

    Shilpa Medicare Raichur facility gets EIR from USFDA

    Medical Dialogues BureauWritten by Medical Dialogues Bureau   |  

    The company announced successful closure of the inspection conducted at its active pharmaceutical ingredient (API) manufacturing site at Raichur with the receipt of EIR from the USFDA, Shilpa Medicare said in a filing to the BSE.


    New Delhi: Pharma firm Shilpa Medicare on Wednesday said it has received an establishment inspection report (EIR) from the US health regulator for its Raichur facility in Karnataka.


    An EIR is given to a unit on successful closure of an inspection conducted by the United States Food and Drug Administration (USFDA).


    The company announced successful closure of the inspection conducted at its active pharmaceutical ingredient (API) manufacturing site at Raichur with the receipt of EIR from the USFDA, Shilpa Medicare said in a filing to the BSE.


    Read Also: Shilpa Medicare gets USFDA approval for a generic equivalent of cancer drug TARCEVA


    The inspection was conducted from July 22-26, 2019, it added.


    Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India. The commercial production in the SML was started in November 1989.

    Read Also: Shilpa Medicare Telangana facility gets EIR from USFDA

    EIREstablishment Inspection ReportinspectionRaichur facilityShilpa MedicareUS Food and Drug AdministrationUSFDA
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      sidekick